Cx 501

Drug Profile

Cx 501

Alternative Names: Cx501

Latest Information Update: 23 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellerix
  • Developer TiGenix
  • Class Cell therapies; Skin disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epidermolysis bullosa

Most Recent Events

  • 31 Aug 2011 Cellerix is divesting Cx 501
  • 05 May 2011 Cellerix has been acquired by TiGenix
  • 19 Nov 2009 Cx 501 is still in phase II trials for Epidermolysis bullosa in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top